Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer

A pilot study

L. Repetto, S. Chiara, T. Guido, M. Bruzzone, C. Oliva, N. Ragni, P. F R Conte Rosso

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In ovarian cancer patients intraperitoneal chemotherapy confers pharmacokinetic advantages and appears an attractive way to improve the efficacy of certain antineoplastic agents. Intraperitoneal carboplatin and interferon alpha have been separately evaluated in ovarian cancer 'with promising results'. We report a phase I-II pilot trial of intraperitoneal carboplatin 400 mg/sqm plus interferon alpha 25 x 106 U q 28 d in 16 patients (pts) previously treated with intravenous cisplatin based chemotherapy. All the patients had relapsed (11 pts) or refractory (5 pts) disease; residual tumors were <2 cm in 10 pts and > 2 cm in 6 pts. Local and general toxicities were moderate, with neither WHO grade 4, nor neurotoxicity and ototoxicity. Myelotoxicity was the most frequent side effect. Among 14 evaluable pts, objective responses were observed in 6 pts (42.8%) including 3 pts with pathologically confirmed complete response (21.4%); six more pts presented prolonged disease-free survival. Response occurred in both categories of pts with > or <2 cm residual disease, also in pts refractory to prior intravenous cisplatin. The proper role of intraperitoneal treatment cannot be exactly defined without large randomized trials designed to compare intraperitoneal to intravenous drug administrations.

Original languageEnglish
Pages (from-to)1641-1643
Number of pages3
JournalAnticancer Research
Volume11
Issue number4
Publication statusPublished - 1991

Fingerprint

Carboplatin
Interferon-alpha
Ovarian Neoplasms
Drug Therapy
Therapeutics
Cisplatin
Residual Neoplasm
Intravenous Administration
Antineoplastic Agents
Disease-Free Survival
Pharmacokinetics

Keywords

  • CBCA
  • IFN
  • Intraperitoneal chemotherapy
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Repetto, L., Chiara, S., Guido, T., Bruzzone, M., Oliva, C., Ragni, N., & Conte Rosso, P. F. R. (1991). Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: A pilot study. Anticancer Research, 11(4), 1641-1643.

Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer : A pilot study. / Repetto, L.; Chiara, S.; Guido, T.; Bruzzone, M.; Oliva, C.; Ragni, N.; Conte Rosso, P. F R.

In: Anticancer Research, Vol. 11, No. 4, 1991, p. 1641-1643.

Research output: Contribution to journalArticle

Repetto, L, Chiara, S, Guido, T, Bruzzone, M, Oliva, C, Ragni, N & Conte Rosso, PFR 1991, 'Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: A pilot study', Anticancer Research, vol. 11, no. 4, pp. 1641-1643.
Repetto, L. ; Chiara, S. ; Guido, T. ; Bruzzone, M. ; Oliva, C. ; Ragni, N. ; Conte Rosso, P. F R. / Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer : A pilot study. In: Anticancer Research. 1991 ; Vol. 11, No. 4. pp. 1641-1643.
@article{640ba020ed7647a2978788d2da8cef4a,
title = "Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: A pilot study",
abstract = "In ovarian cancer patients intraperitoneal chemotherapy confers pharmacokinetic advantages and appears an attractive way to improve the efficacy of certain antineoplastic agents. Intraperitoneal carboplatin and interferon alpha have been separately evaluated in ovarian cancer 'with promising results'. We report a phase I-II pilot trial of intraperitoneal carboplatin 400 mg/sqm plus interferon alpha 25 x 106 U q 28 d in 16 patients (pts) previously treated with intravenous cisplatin based chemotherapy. All the patients had relapsed (11 pts) or refractory (5 pts) disease; residual tumors were <2 cm in 10 pts and > 2 cm in 6 pts. Local and general toxicities were moderate, with neither WHO grade 4, nor neurotoxicity and ototoxicity. Myelotoxicity was the most frequent side effect. Among 14 evaluable pts, objective responses were observed in 6 pts (42.8{\%}) including 3 pts with pathologically confirmed complete response (21.4{\%}); six more pts presented prolonged disease-free survival. Response occurred in both categories of pts with > or <2 cm residual disease, also in pts refractory to prior intravenous cisplatin. The proper role of intraperitoneal treatment cannot be exactly defined without large randomized trials designed to compare intraperitoneal to intravenous drug administrations.",
keywords = "CBCA, IFN, Intraperitoneal chemotherapy, Ovarian cancer",
author = "L. Repetto and S. Chiara and T. Guido and M. Bruzzone and C. Oliva and N. Ragni and {Conte Rosso}, {P. F R}",
year = "1991",
language = "English",
volume = "11",
pages = "1641--1643",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer

T2 - A pilot study

AU - Repetto, L.

AU - Chiara, S.

AU - Guido, T.

AU - Bruzzone, M.

AU - Oliva, C.

AU - Ragni, N.

AU - Conte Rosso, P. F R

PY - 1991

Y1 - 1991

N2 - In ovarian cancer patients intraperitoneal chemotherapy confers pharmacokinetic advantages and appears an attractive way to improve the efficacy of certain antineoplastic agents. Intraperitoneal carboplatin and interferon alpha have been separately evaluated in ovarian cancer 'with promising results'. We report a phase I-II pilot trial of intraperitoneal carboplatin 400 mg/sqm plus interferon alpha 25 x 106 U q 28 d in 16 patients (pts) previously treated with intravenous cisplatin based chemotherapy. All the patients had relapsed (11 pts) or refractory (5 pts) disease; residual tumors were <2 cm in 10 pts and > 2 cm in 6 pts. Local and general toxicities were moderate, with neither WHO grade 4, nor neurotoxicity and ototoxicity. Myelotoxicity was the most frequent side effect. Among 14 evaluable pts, objective responses were observed in 6 pts (42.8%) including 3 pts with pathologically confirmed complete response (21.4%); six more pts presented prolonged disease-free survival. Response occurred in both categories of pts with > or <2 cm residual disease, also in pts refractory to prior intravenous cisplatin. The proper role of intraperitoneal treatment cannot be exactly defined without large randomized trials designed to compare intraperitoneal to intravenous drug administrations.

AB - In ovarian cancer patients intraperitoneal chemotherapy confers pharmacokinetic advantages and appears an attractive way to improve the efficacy of certain antineoplastic agents. Intraperitoneal carboplatin and interferon alpha have been separately evaluated in ovarian cancer 'with promising results'. We report a phase I-II pilot trial of intraperitoneal carboplatin 400 mg/sqm plus interferon alpha 25 x 106 U q 28 d in 16 patients (pts) previously treated with intravenous cisplatin based chemotherapy. All the patients had relapsed (11 pts) or refractory (5 pts) disease; residual tumors were <2 cm in 10 pts and > 2 cm in 6 pts. Local and general toxicities were moderate, with neither WHO grade 4, nor neurotoxicity and ototoxicity. Myelotoxicity was the most frequent side effect. Among 14 evaluable pts, objective responses were observed in 6 pts (42.8%) including 3 pts with pathologically confirmed complete response (21.4%); six more pts presented prolonged disease-free survival. Response occurred in both categories of pts with > or <2 cm residual disease, also in pts refractory to prior intravenous cisplatin. The proper role of intraperitoneal treatment cannot be exactly defined without large randomized trials designed to compare intraperitoneal to intravenous drug administrations.

KW - CBCA

KW - IFN

KW - Intraperitoneal chemotherapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0025751665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025751665&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1641

EP - 1643

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -